Cost-effectiveness of Proton Pump Inhibitor Cotherapy in Patients Taking Long-term, Low-Dose Aspirin for Secondary Cardiovascular Prevention
Authors:
- Sameer D. SainiSSSameer D. Saini
- Philip SchoenfeldPSPhilip Schoenfeld
- A. Mark FendrickAFA. Mark Fendrick
- James ScheimanJSJames Scheiman
- 11 August 2008
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 168 (15) , 1684-1690
Abstract
Background Patients with coronary heart disease (CHD) require long-term therapy with low-dose aspirin (ASA). Although these patients are at increased risk for upper gastrointestinal bleeding (UGIB) and proton pump inhibitor (PPI) cotherapy may reduce such risk, it is not known whether lifelong PPI cotherapy is cost-effective. Methods A Markov model was developed to compare lifelong therapy with ASA alone vs therapy with ASA plus PPI in patients with CHD who are at least 50 years old. Base-case assumptions were (1) starting age, 65 years (range, 50-80 years); (2) UGIB risk category, average risk (range, average to 8-fold increased risk); (3) PPI effectiveness (66% (range, 25%-75%); and (4) annual PPI cost, $250 (range, $250-$1400). Results In the base-case analysis, ASA plus PPI resulted in fewer lifetime UGIB events (3.1% vs 9.5%) and UGIB-related deaths (0.4% vs 1.4%). At over-the-counter (OTC) PPI cost, ASA plus PPI was cost-effective, with an incremental cost-effectiveness ratio (ICER) of $40 090 per life-year saved (LYS). Varying PPI effectiveness from 75% to 25% resulted in ICERs of $35 315 to $94 578 per LYS. Varying the starting age of the cohort from 80 to 50 years resulted in ICERs of $16 887 to $79 955 per LYS. At prescription PPI cost, the ICER for average-risk patients was over $100 000 per LYS across all modeled age groups and assumptions of PPI effectiveness, but the ICER for high-risk patients was $10 433 to $51 505 per LYS. Conclusions At OTC cost, PPI cotherapy is cost-effective in average-risk patients taking low-dose ASA for secondary prevention. At prescription cost, cotherapy is cost-effective for high-risk patients only.Keywords
This publication has 25 references indexed in Scilit:
- Effect of Antisecretory Drugs and Nitrates on the Risk of Ulcer Bleeding Associated With Nonsteroidal Anti-Inflammatory Drugs, Antiplatelet Agents, and AnticoagulantsAmerican Journal of Gastroenterology, 2007
- Systematic Review and Meta-analysis of Adverse Events of Low-dose Aspirin and Clopidogrel in Randomized Controlled TrialsThe American Journal of Medicine, 2006
- Incidence and predictors of upper gastrointestinal bleeding in patients receiving low-dose aspirin for secondary prevention of cardiovascular events in patients with coronary artery diseaseWorld Journal of Gastroenterology, 2006
- A Nationwide Study of Mortality Associated with Hospital Admission Due to Severe Gastrointestinal Events and Those Associated with Nonsteroidal Antiinflammatory Drug UseAmerican Journal of Gastroenterology, 2005
- Clopidogrel versus Aspirin and Esomeprazole to Prevent Recurrent Ulcer BleedingNew England Journal of Medicine, 2005
- Primary Care Management of Chronic Stable Angina and Asymptomatic Suspected or Known Coronary Artery Disease: A Clinical Practice Guideline from the American College of PhysiciansAnnals of Internal Medicine, 2004
- Lansoprazole for the Prevention of Recurrences of Ulcer Complications from Long-Term Low-Dose Aspirin UseNew England Journal of Medicine, 2002
- Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysisBMJ, 2000
- Nitrovasodilators, Low-Dose Aspirin, Other Nonsteroidal Antiinflammatory Drugs, and the Risk of Upper Gastrointestinal BleedingNew England Journal of Medicine, 2000
- Myocardial Infarction Complicating Gastrointestinal HemorrhageMayo Clinic Proceedings, 1999